Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Therapeutic drug monitoring of amikacin in septic patients.

Duszynska W, Taccone FS, Hurkacz M, Kowalska-Krochmal B, Wiela-Hojeńska A, Kübler A.

Crit Care. 2013 Jul 25;17(4):R165. doi: 10.1186/cc12844.

2.

Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.

Delattre IK, Musuamba FT, Nyberg J, Taccone FS, Laterre PF, Verbeeck RK, Jacobs F, Wallemacq PE.

Ther Drug Monit. 2010 Dec;32(6):749-56. doi: 10.1097/FTD.0b013e3181f675c2.

PMID:
20962708
3.

Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin.

Delattre IK, Musuamba FT, Verbeeck RK, Dugernier T, Spapen H, Laterre PF, Wittebole X, Cumps J, Taccone FS, Vincent JL, Jacobs F, Wallemacq PE.

Clin Biochem. 2010 Apr;43(6):589-98. doi: 10.1016/j.clinbiochem.2009.12.007. Epub 2009 Dec 28.

PMID:
20036226
4.

Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.

Delattre IK, Musuamba FT, Jacqmin P, Taccone FS, Laterre PF, Verbeeck RK, Jacobs F, Wallemacq P.

Clin Biochem. 2012 Jul;45(10-11):780-6. doi: 10.1016/j.clinbiochem.2012.03.030. Epub 2012 Apr 5.

PMID:
22503878
5.

Administration of higher doses of amikacin in early stages of sepsis in critically ill patients.

Najmeddin F, Ahmadi A, Mahmoudi L, Sadeghi K, Khalili H, Ahmadvand A, Najafi A, Mojtahedzadeh M.

Acta Med Iran. 2014;52(9):703-9.

6.

Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.

Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA.

Chest. 2012 Jul;142(1):30-39. doi: 10.1378/chest.11-1671.

PMID:
22194591
7.

Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity.

Gálvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E, Illanes V, Llanos O, Castro J.

Int J Antimicrob Agents. 2011 Aug;38(2):146-51. doi: 10.1016/j.ijantimicag.2011.03.022. Epub 2011 May 25.

PMID:
21612894
8.

Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.

Mahmoudi L, Mohammadpour AH, Ahmadi A, Niknam R, Mojtahedzadeh M.

Eur Rev Med Pharmacol Sci. 2013 Feb;17(3):285-91.

9.

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock.

Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, Jacobs F.

Crit Care. 2010;14(2):R53. doi: 10.1186/cc8945. Epub 2010 Apr 6.

10.

Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation.

Peris-Marti JF, Borras-Blasco J, Rosique-Robles JD, Gonzalez-Delgado M.

J Clin Pharm Ther. 2004 Feb;29(1):65-70.

PMID:
14748900
11.

Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.

Roger C, Nucci B, Louart B, Friggeri A, Knani H, Evrard A, Lavigne JP, Allaouchiche B, Lefrant JY, Roberts JA, Muller L.

J Antimicrob Chemother. 2016 Jan;71(1):208-12. doi: 10.1093/jac/dkv291. Epub 2015 Oct 1.

PMID:
26429564
12.

[Therapeutic monitoring of intravenous vancomycin in a pediatric critical care unit].

Villena R, González CA, Nalegach ME, Vásquez A, Villareal M, Drago M.

Rev Chilena Infectol. 2014 Jun;31(3):249-53. doi: 10.4067/S0716-10182014000300001. Spanish.

13.

Increased amikacin dosage requirements in burn patients receiving a once-daily regimen.

Conil JM, Georges B, Breden A, Segonds C, Lavit M, Seguin T, Coley N, Samii K, Chabanon G, Houin G, Saivin S.

Int J Antimicrob Agents. 2006 Sep;28(3):226-30. Epub 2006 Aug 14.

PMID:
16908121
14.

The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.

Abdel-Hady E, El Hamamsy M, Hedaya M, Awad H.

J Clin Pharm Ther. 2011 Feb;36(1):45-52. doi: 10.1111/j.1365-2710.2009.01152.x.

PMID:
21198719
15.

Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients.

Petejova N, Zahalkova J, Duricova J, Kacirova I, Brozmanova H, Urbanek K, Grundmann M, Martinek A.

J Chemother. 2012 Apr;24(2):107-12. doi: 10.1179/1120009X12Z.0000000006.

PMID:
22546767
16.

Therapeutic drug monitoring of amikacin in preterm and term infants.

Siddiqi A, Khan DA, Khan FA, Razzaq A.

Singapore Med J. 2009 May;50(5):486-9.

17.

Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.

Zazo H, Martín-Suárez A, Lanao JM.

Int J Antimicrob Agents. 2013 Aug;42(2):155-60. doi: 10.1016/j.ijantimicag.2013.04.021. Epub 2013 Jun 5.

PMID:
23756322
18.

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine.

Crit Care Med. 2008 Jan;36(1):296-327. Erratum in: Crit Care Med. 2008 Apr;36(4):1394-6.

PMID:
18158437
19.

Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.

Pajot O, Burdet C, Couffignal C, Massias L, Armand-Lefevre L, Foucrier A, Da Silva D, Lasocki S, Laouénan C, Mentec H, Mentré F, Wolff M.

J Antimicrob Chemother. 2015 May;70(5):1487-94. doi: 10.1093/jac/dku569. Epub 2015 Jan 27.

PMID:
25630642
20.

Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.

Georges B, Conil JM, Cougot P, Decun JF, Archambaud M, Seguin T, Chabanon G, Virenque C, Houin G, Saivin S.

Int J Clin Pharmacol Ther. 2005 Aug;43(8):360-9.

PMID:
16119511

Supplemental Content

Support Center